Seres Therapeutics, Inc. (MCRB)
After hours:
- Business Wire
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
- Simply Wall St.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Revenue Estimates By 59%
Market forces rained on the parade of Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders today, when the analysts...
- Zacks
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
